PTK/ZK is an oral angiogenesis inhibitor that selectively inhibits the tyrosine kinase domains of vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) receptor, and c-KIT. PTK/ZK in combination with oxaliplatin and 5-FU and leucovorin has completed phase III trials as 1st line therapy and 2nd line therapy, (after irinotecan-based chemotherapy), in advanced metastatic colorectal cancer. Results should be available during 2005.